Decoy Therapeutics (NASDAQ:DCOY) Stock Short Interest Rises 1,321.2%

Decoy Therapeutics (NASDAQ:DCOY) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 150,336 shares, a growth of 1,321.2% from the September 15th total of 10,578 shares. Approximately 23.3% of the company’s stock are short sold. Based on an average daily volume of 11,986,981 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Decoy Therapeutics in a report on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Stock Down 3.3%

Shares of DCOY traded down $0.05 during trading hours on Friday, reaching $1.47. The company’s stock had a trading volume of 43,686 shares, compared to its average volume of 6,830,394. The firm has a market cap of $970,200.00, a price-to-earnings ratio of -0.05 and a beta of 0.65. Decoy Therapeutics has a 1-year low of $1.46 and a 1-year high of $55.92. The company has a 50 day moving average of $2.94 and a two-hundred day moving average of $4.99.

Decoy Therapeutics (NASDAQ:DCOY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($4.46) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter. As a group, analysts forecast that Decoy Therapeutics will post -8.96 EPS for the current fiscal year.

Decoy Therapeutics Company Profile

Decoy Therapeutics, Inc is a biotechnology company focused on discovering and developing antiviral medicines. The company’s research is based on the use of engineered “decoy” molecules designed to interfere with interactions between viruses and human cells, with the goal of preventing viral infection or limiting disease progression.

Decoy Therapeutics is developing a pipeline of investigational therapies intended to address viral diseases. Its platform is focused on creating treatments that may have activity against multiple viral strains or variants, although specific products, development stages and commercialization plans may change as the company advances its research programs.

Publicly available information about Decoy Therapeutics’ leadership, operating geographies and corporate history is limited.